{"id":69120,"date":"2023-10-05T15:26:13","date_gmt":"2023-10-05T19:26:13","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/viatris-makes-progress-on-ozempic-patent-challenge\/"},"modified":"2023-10-05T15:26:16","modified_gmt":"2023-10-05T19:26:16","slug":"viatris-makes-progress-on-ozempic-patent-challenge","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=69120","title":{"rendered":"Viatris makes progress on Ozempic patent challenge"},"content":{"rendered":"
\n

The U.S. Patent and Trademark Office\u2019s patent trial and appeal board has agreed to review a Novo Nordisk
\n NVO,
\n +1.04%<\/bg-quote>
\n patent covering certain strengths of Ozempic, a Viatris
\n VTRS,
\n -0.57%<\/bg-quote>
\n spokesperson said Wednesday. The patent challenge was filed by Mylan Pharmaceuticals, which is now part of Viatris. <\/p>\n

Viatris is \u201cpleased\u201d with the board\u2019s decision to review the validity of the patent, and a final written decision is expected in October 2024, the spokesperson said. <\/p>\n

\n

In the decision dated Wednesday, the patent trial and appeal board said that based on the arguments and evidence presented thus far, the board is persuaded that Mylan \u201chas demonstrated a reasonable likelihood that it would prevail with respect to at least one claim challenged in the petition.\u201d <\/p>\n

Novo Nordisk said in a statement Wednesday that it \u201cwill vigorously defend the company\u2019s intellectual property in this matter,\u201d adding that it cannot comment further as the dispute is ongoing. <\/p>\n

The decision comes after the patent trial and appeal board earlier this week declined to review two other Mylan challenges to patents covering semaglutide, the active ingredient in Ozempic and Wegovy, which is also made by Novo Nordisk. The Viatris spokesperson said that the company also \u201cfirmly believes that these patents are invalid and will continue to vigorously challenge their validity\u201d in court. <\/p>\n

Viatris shares gained 0.5% on Wednesday and are down 12.9% in the year to date, while Novo Nordisk\u2019s American depositary receipts gained 1.4% Wednesday and are up 31.6% so far this year. <\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The U.S. Patent and Trademark Office\u2019s patent trial and appeal board has agreed to review a Novo Nordisk NVO, +1.04% patent covering certain strengths of Ozempic, a Viatris VTRS, -0.57% spokesperson said Wednesday. The patent challenge was filed by Mylan Pharmaceuticals, which is now part of Viatris. Viatris is \u201cpleased\u201d with the board\u2019s decision to […]<\/p>\n","protected":false},"author":1,"featured_media":69121,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-69120","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"\nViatris makes progress on Ozempic patent challenge | iFintechWorld<\/title>\n<meta name=\"description\" content=\"The U.S. Patent and Trademark Office\u2019s patent trial and appeal board has agreed to review a Novo Nordisk NVO, +1.04% patent covering certain strengths of\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=69120\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viatris makes progress on Ozempic patent challenge | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"The U.S. Patent and Trademark Office\u2019s patent trial and appeal board has agreed to review a Novo Nordisk NVO, +1.04% patent covering certain strengths of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=69120\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-05T19:26:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-05T19:26:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/10\/1696533974_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=69120#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=69120\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Viatris makes progress on Ozempic patent challenge\",\"datePublished\":\"2023-10-05T19:26:13+00:00\",\"dateModified\":\"2023-10-05T19:26:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=69120\"},\"wordCount\":258,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=69120#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=69120\",\"url\":\"https:\/\/ifintechworld.com\/?p=69120\",\"name\":\"Viatris makes progress on Ozempic patent challenge | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-10-05T19:26:13+00:00\",\"dateModified\":\"2023-10-05T19:26:16+00:00\",\"description\":\"The U.S. Patent and Trademark Office\u2019s patent trial and appeal board has agreed to review a Novo Nordisk NVO, +1.04% patent covering certain strengths of\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=69120#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=69120\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=69120#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viatris makes progress on Ozempic patent challenge\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viatris makes progress on Ozempic patent challenge | iFintechWorld","description":"The U.S. Patent and Trademark Office\u2019s patent trial and appeal board has agreed to review a Novo Nordisk NVO, +1.04% patent covering certain strengths of","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=69120","og_locale":"en_US","og_type":"article","og_title":"Viatris makes progress on Ozempic patent challenge | iFintechWorld","og_description":"The U.S. Patent and Trademark Office\u2019s patent trial and appeal board has agreed to review a Novo Nordisk NVO, +1.04% patent covering certain strengths of","og_url":"https:\/\/ifintechworld.com\/?p=69120","og_site_name":"iFintechWorld","article_published_time":"2023-10-05T19:26:13+00:00","article_modified_time":"2023-10-05T19:26:16+00:00","og_image":[{"width":1280,"height":640,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/10\/1696533974_social.jpeg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=69120#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=69120"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Viatris makes progress on Ozempic patent challenge","datePublished":"2023-10-05T19:26:13+00:00","dateModified":"2023-10-05T19:26:16+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=69120"},"wordCount":258,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=69120#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=69120","url":"https:\/\/ifintechworld.com\/?p=69120","name":"Viatris makes progress on Ozempic patent challenge | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-10-05T19:26:13+00:00","dateModified":"2023-10-05T19:26:16+00:00","description":"The U.S. Patent and Trademark Office\u2019s patent trial and appeal board has agreed to review a Novo Nordisk NVO, +1.04% patent covering certain strengths of","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=69120#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=69120"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=69120#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Viatris makes progress on Ozempic patent challenge"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/69120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69120"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/69120\/revisions"}],"predecessor-version":[{"id":69122,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/69120\/revisions\/69122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/69121"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}